Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

A. Schweizer; S. Dejager; J. E. Foley; A. Couturier; M. Ligueros-Saylan; W. Kothny

首页> 外文期刊>Diabetes, Obesity and Metabolism >Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

【24h】

Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

机译：评估维格列汀的心脑血管安全性：对来自大型III期2型糖尿病人群的裁决事件的荟萃分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: To assess the cardiovascular and cerebrovascular (CCV) safety of the dipeptidyl peptidase-IV inhibitor vildagliptin.

机译：目的：评估二肽基肽酶-IV抑制剂维格列汀在心血管和脑血管（CCV）的安全性。

著录项

来源
《Diabetes, Obesity and Metabolism》 |2010年第6期|485-494|共10页
作者
A. Schweizer; S. Dejager; J. E. Foley; A. Couturier; M. Ligueros-Saylan; W. Kothny;
展开▼
作者单位

Novartis Pharma AG Basel Switzerland;

Novartis Pharma SAS Rueil-Malmaison France;

Novartis Pharmaceuticals Corporation East Hanover NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
cardiovascular risk; diabetes; dipeptidyl peptidase-4;

机译：心血管风险;糖尿病;二肽基肽酶-4;

相似文献

外文文献
中文文献
专利

1. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. [J] . Schweizer A, Dejager S, Foley JE, Diabetes, obesity & metabolism . 2010,第6期

机译：评估维格列汀的心脑血管安全性：来自大量III期2型糖尿病人群的裁决事件的荟萃分析。
2. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events [J] . Keith C. Ferdinand, Fady T. Botros, Charles M. Atisso, Cardiovascular Diabetology . 2016,第1期

机译：每周一次的2型糖尿病患者中dulaglutide的心血管安全性：预先确定的前瞻性心血管事件的荟萃分析
3. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme [J] . Odd E Johansen, Dietmar Neubacher, Maximilian von Eynatten, Cardiovascular Diabetology . 2012,第1期

机译：利格列汀对2型糖尿病患者的心血管安全性：3期计划的既定，前瞻性和裁决性荟萃分析
4. Prevention of stress-induced cardio- and cerebrovascular disturbances by low-power laser irradiation [C] . Tatiana P. Romanova, Saratov State Medical Univ., Saratov, Effects of Low-Power Light on Biological Systems . 1996

机译：低功率激光辐照预防压力诱发的心脑血管疾病
5. Meta-analysis of the relationship between ethnicity, obesity, and type 2 diabetes of adult in urban populations of Central America [D] . Wuenstel, William G. 2012

机译：对中美洲城市人口的成人种族，肥胖与2型糖尿病之间关系的荟萃分析
6. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events [O] . Keith C. Ferdinand, Fady T. Botros, Charles M. Atisso, 2016

机译：每周一次的dulaglutide在2型糖尿病中的心血管安全性：预先确定的前瞻性心血管事件的荟萃分析
7. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population [O] . A. Schweizer, S. Dejager, J. E. Foley, 2010

机译：评估Vildagliptin的心血管血管安全：Meta分析来自大期III型糖尿病群的判决事件

Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

摘要

著录项

相似文献

相关主题

期刊订阅